がん/腫瘍プロファイリング市場：バイオマーカータイプ別（遺伝子、タンパク質）技術別（NGS、PCR、ISH、IHC）がんタイプ別（乳がん、肺がん、大腸がん、前立腺がん、白血病）アプリケーション別（臨床、研究）エンドユーザー別（製薬、学術、CRO）-2030年までの世界予測

がん/腫瘍プロファイリング市場：バイオマーカータイプ別（遺伝子、タンパク質）技術別（NGS、PCR、ISH、IHC）がんタイプ別（乳がん、肺がん、大腸がん、前立腺がん、白血病）アプリケーション別（臨床、研究）エンドユーザー別（製薬、学術、CRO）-2030年までの世界予測

世界のがん/腫瘍プロファイリング市場は、2023年から2030年までのCAGR20.9%で、2030年までに223億米ドルに達すると予測されます。

広範な2次調査と1次調査、市場シナリオの詳細な分析を経て、当レポートは主要産業の促進要因・抑制要因・課題・機会の分析から構成されています。がん/腫瘍プロファイリング市場の成長は、がんの有病率の増加、医薬品研究開発費の増加、標的療法の増加と新しい実用的なバイオマーカーの発見、がん研究への投資の増加、NGSベースのプロファイリングのコスト低下、マルチオミクス腫瘍プロファイリングの進歩に起因しています。しかし、NGSセットアップに必要な高額な設備投資と長いターンアラウンドタイムがこの市場の成長を抑制しています。

さらに、個別化医薬品の開発への注目の高まり、標的治療に対する認識と採用の高まりは、市場成長の機会を生み出すと予想されます。しかし、結果を解釈する遺伝子専門家の不足、社内で腫瘍プロファイリング技術を利用できないこと、バイオマーカーの誤発見が多いことは、がん／腫瘍プロファイリング市場の利害関係者にとって大きな課題です。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場洞察

• 市場
• 概要
• 市場成長への影響要因
  • 市場力学の影響分析
  • 要因分析
• 規制分析
  • 北米
    • 米国
    • 日本
    • インド
    • カナダ
  • 欧州
  • アジア太平洋
    • 中国
    • 日本
    • インド
  • ラテンアメリカ
  • 中東
• ポーターのファイブフォース分析

第5章 がん/腫瘍プロファイリング市場のバイオマーカータイプ別評価

• 概要
• 遺伝子バイオマーカー
• タンパク質バイオマーカー

第6章 がん/腫瘍プロファイリング市場：がんタイプ別評価

• 概要
• 乳がん
• 大腸がん
• 肺がん
• 前立腺がん
• リンパ腫
• 白血病
• 子宮頸がん
• その他のがん

第7章 がん／腫瘍プロファイリング市場の技術別評価

• 概要
• 次世代シーケンサー（NGS）
• ポリメラーゼ連鎖反応（PCR）
• インサイチュハイブリダイゼーション（ISH）
• 免疫組織化学（IHC）
• その他の技術

第8章 がん／腫瘍プロファイリング市場：アプリケーション別評価

• 概要
• 調査アプリケーション
• 臨床アプリケーション

第9章 がん/腫瘍プロファイリング市場評価：エンドユーザー別

• 概要
• 製薬・バイオ製薬企業
• 病院・診断研究所
• 学術・研究機関
• CRO（医薬品開発業務受託機関）

第10章 地域別がん/腫瘍プロファイリング市場評価

• 概要
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• ラテンアメリカ
• 中東・アフリカ

第11章 競合分析

• 概要
• 主要成長戦略
• 競合ベンチマーキング
• 市場シェア分析（2022年）
  • Thermo Fisher Scientific Inc.（U.S.）
  • Illumina, Inc.（U.S.）
  • F. Hoffmann-La Roche Ltd（Switzerland）
  • Exact Sciences Corporation（U.S.）
  • Qiagen N.V.（Netherlands）
• 競合ダッシュボード
  • 業界リーダー
  • 市場差別化要因
  • 先行企業
  • 新興企業

第12章 企業プロファイル

• Thermo Fisher Scientific, Inc.
• Illumina, Inc.
• Qiagen N.V.
• F. Hoffmann-La Roche Ltd
• Exact Sciences Corporation
• Agilent Technologies, Inc.
• NanoString Technologies, Inc.
• HTG Molecular Diagnostics, Inc.
• Agendia Inc.
• Personalis, Inc.
• Tempus Labs, Inc.

第13章 付録

• Table 1 Major Targeted Therapies and Corresponding Biomarkers
• Table 2 Number of New Cancer Cases, by Type, 2020 Vs. 2030
• Table 3 Regulatory Authorities Governing In Vitro Diagnostics, by Country/Region
• Table 4 Global Cancer/Tumor Profiling Market, by Biomarker Type, 2021-2030 (USD Million)
• Table 5 Germline Mutations in Hereditary Cancer Syndromes: Cancer-Causing Genes as Biomarkers of Risk
• Table 6 Global Cancer/Tumor Profiling Market for Genetic Biomarkers, by Country/Region, 2021-2030 (USD Million)
• Table 7 Global Cancer/Tumor Profiling Market for Protein Biomarkers, by Country/Region, 2021-2030 (USD Million)
• Table 8 Global Cancer/Tumor Profiling Market, by Cancer Type, 2021-2030 (USD MILLION)
• Table 9 Number of New Breast Cancer Cases Globally (2020-2035)
• Table 10 Global Cancer/Tumor Profiling Market for Breast Cancer, by Country/Region, 2021-2030 (USD Million)
• Table 11 Global Cancer/Tumor Profiling Market for Colorectal Cancer, by Country/Region, 2021-2030 (USD Million)
• Table 12 Global Cancer/Tumor Profiling Market for Lung Cancer, by Country/Region, 2021-2030 (USD Million)
• Table 13 Number of New Prostate Cancer Cases (2020-2035)
• Table 14 Global Cancer/Tumor Profiling Market for Prostate Cancer, by Country/Region, 2021-2030 (USD Million)
• Table 15 Number of New Non-Hodgkin Lymphoma Cancer Cases (2020-2035)
• Table 16 Global Cancer/Tumor Profiling Market for Lymphoma, by Country/Region, 2021-2030 (USD Million)
• Table 17 Estimated Number of New Leukemia Cases (2020-2035)
• Table 18 Global Cancer/Tumor Profiling Market for Leukemia, by Country/Region, 2021-2030 (USD Million)
• Table 19 Global Cancer/Tumor Profiling Market for Cervical Cancer, by Country/Region, 2021-2030 (USD Million)
• Table 20 Number of New Cancer Cases (2020-2035)
• Table 21 Global Cancer/Tumor Profiling Market for Other Cancer Types, by Country/Region, 2021-2030 (USD Million)
• Table 22 Global Cancer/Tumor Profiling Market, by Technology, 2021-2030 (USD Million)
• Table 23 Global Next-Generation Sequencing (NGS) Cancer/Tumor Profiling Market, by Country/Region, 2021-2030 (USD Million)
• Table 24 Global Polymerase Chain Reaction (PCR) Cancer/Tumor Profiling Market, by Country/Region, 2021-2030 (USD Million)
• Table 25 Global In Situ Hybridization Cancer/Tumor Profiling Market, by Country/Region, 2021-2030 (USD Million)
• Table 26 Applications of IHC in Oncology and Related Antibodies
• Table 27 Global Immunohistochemistry (IHC) Cancer/Tumor Profiling Market, by Country/Region, 2021-2030 (USD Million)
• Table 28 Global Other Technologies Cancer/Tumor Profiling Market, by Country/Region, 2021-2030 (USD Million)
• Table 29 Global Cancer/Tumor Profiling Market, by Application, 2021-2030 (USD Million)
• Table 30 Currently Available Targeted Therapies and Corresponding Biomarkers
• Table 31 Global Cancer/Tumor Profiling Market for Research Applications, by Country/Region, 2021-2030 (USD Million)
• Table 32 Frequently Used Clinical Tumor Markers
• Table 33 Global Cancer/Tumor Profiling Market for Clinical Applications, by Country/Region, 2021-2030 (USD Million)
• Table 34 Global Cancer/Tumor Profiling Market, by End User, 2021-2030 (USD Million)
• Table 35 Global Cancer/Tumor Profiling Market for Pharmaceutical & Biopharmaceutical Companies, by Country/Region, 2021-2030 (USD Million)
• Table 36 Global Cancer/Tumor Profiling Market for Hospitals & Diagnostic Laboratories, by Country/Region, 2021-2030 (USD Million)
• Table 37 Global Cancer/Tumor Profiling Market for Academic & Research Institutes, by Country/Region, 2021-2030 (USD Million)
• Table 38 Global Cancer/Tumor Profiling Market for CROs, by Country/Region, 2021-2030 (USD Million)
• Table 39 Global Cancer/Tumor Profiling Market, by Region, 2021-2030 (USD Million)
• Table 40 Estimated Cancer Cases in North America: 2020-2030
• Table 41 North America: Cancer/Tumor Profiling Market, by Country, 2021-2030 (USD Million)
• Table 42 North America: Cancer/Tumor Profiling Market, by Biomarker Type, 2021-2030 (USD Million)
• Table 43 North America: Cancer/Tumor Profiling Market, by Technology, 2021-2030 (USD Million)
• Table 44 North America: Cancer/Tumor Profiling Market, by Cancer Type, 2021-2030 (USD Million)
• Table 45 North America: Cancer/Tumor Profiling Market, by Application, 2021-2030 (USD Million)
• Table 46 North America: Cancer/Tumor Profiling Market, by End User, 2021-2030 (USD Million)
• Table 47 U.S.: Key Macro & Micro Indicators
• Table 48 U.S.: Cancer/Tumor Profiling Market, by Biomarker Type, 2021-2030 (USD Million)
• Table 49 U.S.: Cancer/Tumor Profiling Market, by Technology, 2021-2030 (USD Million)
• Table 50 U.S.: Cancer/Tumor Profiling Market, by Cancer Type, 2021-2030 (USD Million)
• Table 51 U.S.: Cancer/Tumor Profiling Market, by Application, 2021-2030 (USD Million)
• Table 52 U.S.: Cancer/Tumor Profiling Market, by End User, 2021-2030 (USD Million)
• Table 53 Canada: Key Macro & Micro Indicators
• Table 54 Canada: Cancer/Tumor Profiling Market, by Biomarker Type, 2021-2030 (USD Million)
• Table 55 Canada: Cancer/Tumor Profiling Market, by Technology, 2021-2030 (USD Million)
• Table 56 Canada: Cancer/Tumor Profiling Market, by Cancer Type, 2021-2030 (USD Million)
• Table 57 Canada: Cancer/Tumor Profiling Market, by Application, 2021-2030 (USD Million)
• Table 58 Canada: Cancer/Tumor Profiling Market, by End User, 2021-2030 (USD Million)
• Table 59 Europe: Cancer/Tumor Profiling Market, by Country, 2021-2030 (USD Million)
• Table 60 Europe: Cancer/Tumor Profiling Market, by Biomarker Type, 2021-2030 (USD Million)
• Table 61 Europe: Cancer/Tumor Profiling Market, by Technology, 2021-2030 (USD Million)
• Table 62 Europe: Cancer/Tumor Profiling Market, by Cancer Type, 2021-2030 (USD Million)
• Table 63 Europe: Cancer/Tumor Profiling Market, by Application, 2021-2030 (USD Million)
• Table 64 Europe: Cancer/Tumor Profiling Market, by End User, 2021-2030 (USD Million)
• Table 65 Germany: Key Macro & Micro Indicators
• Table 66 Germany: Cancer/Tumor Profiling Market, by Biomarker Type, 2021-2030 (USD Million)
• Table 67 Germany: Cancer/Tumor Profiling Market, by Technology, 2021-2030 (USD Million)
• Table 68 Germany: Cancer/Tumor Profiling Market, by Cancer Type, 2021-2030 (USD Million)
• Table 69 Germany: Cancer/Tumor Profiling Market, by Application, 2021-2030 (USD Million)
• Table 70 Germany: Cancer/Tumor Profiling Market, by End User, 2021-2030 (USD Million)
• Table 71 France: Key Macro & Indicators
• Table 72 France: Cancer/Tumor Profiling Market, by Biomarker Type, 2021-2030 (USD Million)
• Table 73 France: Cancer/Tumor Profiling Market, by Technology, 2021-2030 (USD Million)
• Table 74 France: Cancer/Tumor Profiling Market, by Cancer Type, 2021-2030 (USD Million)
• Table 75 France: Cancer/Tumor Profiling Market, by Application, 2021-2030 (USD Million)
• Table 76 France: Cancer/Tumor Profiling Market, by End User, 2021-2030 (USD Million)
• Table 77 U.K.: Key Macro & Micro Indicators
• Table 78 U.K.: Cancer/Tumor Profiling Market, by Biomarker Type, 2021-2030 (USD Million)
• Table 79 U.K.: Cancer/Tumor Profiling Market, by Technology, 2021-2030 (USD Million)
• Table 80 U.K.: Cancer/Tumor Profiling Market, by Cancer Type, 2021-2030 (USD Million)
• Table 81 U.K.: Cancer/Tumor Profiling Market, by Application, 2021-2030 (USD Million)
• Table 82 U.K.: Cancer/Tumor Profiling Market, by End User, 2021-2030 (USD Million)
• Table 83 Italy: Key Macro & Micro Indicators
• Table 84 Italy: Cancer/Tumor Profiling Market, by Biomarker Type, 2021-2030 (USD Million)
• Table 85 Italy: Cancer/Tumor Profiling Market, by Technology, 2021-2030 (USD Million)
• Table 86 Italy: Cancer/Tumor Profiling Market, by Cancer Type, 2021-2030 (USD Million)
• Table 87 Italy: Cancer/Tumor Profiling Market, by Application, 2021-2030 (USD Million)
• Table 88 Italy: Cancer/Tumor Profiling Market, by End User, 2021-2030 (USD Million)
• Table 89 Spain: Key Macro & Micro Indicators
• Table 90 Spain: Cancer/Tumor Profiling Market, by Biomarker Type, 2021-2030 (USD Million)
• Table 91 Spain: Cancer/Tumor Profiling Market, by Technology, 2021-2030 (USD Million)
• Table 92 Spain: Cancer/Tumor Profiling Market, by Cancer Type, 2021-2030 (USD Million)
• Table 93 Spain: Cancer/Tumor Profiling Market, by Application, 2021-2030 (USD Million)
• Table 94 Spain: Cancer/Tumor Profiling Market, by End User, 2021-2030 (USD Million)
• Table 95 Estimated Number of New Cancer Cases, by Country, 2020 Vs. 2030
• Table 96 Rest of Europe: Cancer/Tumor Profiling Market, by Biomarker Type, 2021-2030 (USD Million)
• Table 97 Rest of Europe: Cancer/Tumor Profiling Market, by Technology, 2021-2030 (USD Million)
• Table 98 Rest of Europe: Cancer/Tumor Profiling Market, by Cancer Type, 2021-2030 (USD Million)
• Table 99 Rest of Europe: Cancer/Tumor Profiling Market, by Application, 2021-2030 (USD Million)
• Table 100 Rest of Europe: Cancer/Tumor Profiling Market, by End User, 2021-2030 (USD Million)
• Table 101 Asia-Pacific: Cancer/Tumor Profiling Market, by Country/Region, 2021-2030 (USD Million)
• Table 102 Asia-Pacific: Cancer/Tumor Profiling Market, by Biomarker Type, 2021-2030 (USD Million)
• Table 103 Asia-Pacific: Cancer/Tumor Profiling Market, by Technology, 2021-2030 (USD Million)
• Table 104 Asia-Pacific: Cancer/Tumor Profiling Market, by Cancer Type, 2021-2030 (USD Million)
• Table 105 Asia-Pacific: Cancer/Tumor Profiling Market, by Application, 2021-2030 (USD Million)
• Table 106 Asia-Pacific: Cancer/Tumor Profiling Market, by End User, 2021-2030 (USD Million)
• Table 107 China: Key Macro & Micro Indicators
• Table 108 China: Cancer/Tumor Profiling Market, by Biomarker Type, 2021-2030 (USD Million)
• Table 109 China: Cancer/Tumor Profiling Market, by Technology, 2021-2030 (USD Million)
• Table 110 China: Cancer/Tumor Profiling Market, by Cancer Type, 2021-2030 (USD Million)
• Table 111 China: Cancer/Tumor Profiling Market, by Application, 2021-2030 (USD Million)
• Table 112 China: Cancer/Tumor Profiling Market, by End User, 2021-2030 (USD Million)
• Table 113 Japan: Key Macro & Micro Indicators
• Table 114 Japan: Cancer/Tumor Profiling Market, by Biomarker Type, 2021-2030 (USD Million)
• Table 115 Japan: Cancer/Tumor Profiling Market, by Technology, 2021-2030 (USD Million)
• Table 116 Japan: Cancer/Tumor Profiling Market, by Cancer Type, 2021-2030 (USD Million)
• Table 117 Japan: Cancer/Tumor Profiling Market, by Application, 2021-2030 (USD Million)
• Table 118 Japan: Cancer/Tumor Profiling Market, by End User, 2021-2030 (USD Million)
• Table 119 India: Key Macro & Micro Indicators
• Table 120 India: Cancer/Tumor Profiling Market, by Biomarker Type, 2021-2030 (USD Million)
• Table 121 India: Cancer/Tumor Profiling Market, by Technology, 2021-2030 (USD Million)
• Table 122 India: Cancer/Tumor Profiling Market, by Cancer Type, 2021-2030 (USD Million)
• Table 123 India: Cancer/Tumor Profiling Market, by Application, 2021-2030 (USD Million)
• Table 124 India: Cancer/Tumor Profiling Market, by End User, 2021-2030 (USD Million)
• Table 125 Estimated Number of New Cancer Cases, by Country, 2020 Vs. 2030
• Table 126 Rest of Asia-Pacific: Cancer/Tumor Profiling Market, by Biomarker Type, 2021-2030 (USD Million)
• Table 127 Rest of Asia-Pacific: Cancer/Tumor Profiling Market, by Technology, 2021-2030 (USD Million)
• Table 128 Rest of Asia-Pacific: Cancer/Tumor Profiling Market, by Cancer Type, 2021-2030 (USD Million)
• Table 129 Rest of Asia-Pacific: Cancer/Tumor Profiling Market, by Application, 2021-2030 (USD Million)
• Table 130 Rest of Asia-Pacific: Cancer/Tumor Profiling Market, by End User, 2021-2030 (USD Million)
• Table 131 Latin America: Cancer/Tumor Profiling Market, by Biomarker Type, 2021-2030 (USD Million)
• Table 132 Latin America: Cancer/Tumor Profiling Market, by Technology, 2021-2030 (USD Million)
• Table 133 Latin America: Cancer/Tumor Profiling Market, by Cancer Type, 2021-2030 (USD Million)
• Table 134 Latin America: Cancer/Tumor Profiling Market, by Application, 2021-2030 (USD Million)
• Table 135 Latin America: Cancer/Tumor Profiling Market, by End User, 2021-2030 (USD Million)
• Table 136 Middle East & Africa: Cancer/Tumor Profiling Market, by Biomarker Type, 2021-2030 (USD Million)
• Table 137 Middle East & Africa: Cancer/Tumor Profiling Market, by Technology, 2021-2030 (USD Million)
• Table 138 Middle East & Africa: Cancer/Tumor Profiling Market, by Cancer Type, 2021-2030 (USD Million)
• Table 139 Middle East & Africa: Cancer/Tumor Profiling Market, by Application, 2021-2030 (USD Million)
• Table 140 Middle East & Africa: Cancer/Tumor Profiling Market, by End User, 2021-2030 (USD Million)
• Table 141 Recent Developments, by Company, 2020-2023

Cancer/Tumor Profiling Market by Biomarker Type (Genetic, Protein) Technology (NGS, PCR, ISH, IHC) Cancer Type (Breast, Lung, Colorectal, Prostate, Leukemia) Application (Clinical, Research) End User (Pharma, Academic, CRO)-Global Forecast to 2030

The global cancer/tumor profiling market is projected to reach $22.3 billion by 2030, at a CAGR of 20.9% from 2023 to 2030.

Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of the cancer/tumor profiling market is attributed to the increasing prevalence of cancer, the rising pharmaceutical R&D expenditures, the growing number of targeted therapies and the discovery of new actionable biomarkers, increasing investments in cancer research, the declining costs of NGS-based profiling, and advancements in multi-omics tumor profiling. However, the high capital investments required for NGS setups and long turnaround times restrain the growth of this market.

Additionally, the increasing focus on developing personalized medicines and the rising awareness and adoption of targeted therapies are expected to generate market growth opportunities. However, the lack of genetic experts for interpreting results, the non-availability of in-house tumor profiling technologies, and the high number of false biomarker discoveries are major challenges for the stakeholders in the cancer/tumor profiling market.

Based on biomarker type, in 2023, the genetic biomarkers segment is expected to account for the largest share of the market. The large market share of this segment is attributed to the effectiveness of genetic biomarkers as targets for therapeutic treatments, their role in enhancing treatment delivery, and their utility in facilitating convenient disease diagnosis.

Based on technology, in 2023, the next-generation sequencing (NGS) segment is expected to account for the largest share of the market. The large market share of the segment is attributed to the growing adoption of NGS in cancer/tumor profiling, its ability to provide faster and more accurate genetic testing, the rapidly declining cost of sequencing per base, and the introduction of cost-effective benchtop laboratory sequencers.

Based on cancer type, the cancer/tumor profiling market is segmented into breast cancer, colorectal cancer, lung cancer, prostate cancer, lymphoma, leukemia, cervical cancer, and other cancer types. In 2023, the breast cancer segment is expected to account for the largest share of the cancer/tumor profiling market. The increase in breast cancer cases, government initiatives promoting breast cancer treatment, increasing healthcare expenditure, and reimbursement for certain profiling technologies such as NGS have propelled the demand for cancer/tumor profiling for breast cancer.

Based on application, the research applications segment is expected to account for the largest share of the market. The large market share of this segment is attributed to the rising incidence of cancer, the growing demand for precision medicine, the increased discovery of biomarkers, and the availability of cost-effective advanced profiling technologies like NGS and PCR for research applications.

Based on end user, in 2023, the pharmaceutical & biopharmaceutical companies segment is expected to account for the largest share of the market. The large market share of this segment is attributed to the declining costs of sequencing, the development of companion diagnostics and precision medicine, and the high demand for cancer/tumor profiling from pharmaceutical and biopharmaceutical companies, primarily for biomarker discovery purposes.

An in-depth analysis of the geographical scenario of the global cancer/tumor profiling market provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2023, North America is expected to account for the largest share of the cancer/tumor profiling market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America's significant market share can be attributed to factors such as the rising burden of cancer, the presence of key market players, well-established healthcare infrastructure, and government initiatives aimed at bolstering cancer research efforts.

The key players operating in the global cancer/tumor profiling market are Thermo Fisher Scientific Inc. (U.S.), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (U.S.), NanoString Technologies, Inc. (U.S.), HTG Molecular Diagnostics, Inc. (U.S.), Agendia Inc. (U.S.), Personalis, Inc. (U.S.), Exact Sciences Corporation (U.S.), and Tempus Labs, Inc. (U.S.).

Scope of the Report:

Cancer/Tumor Profiling Market Assessment-by Biomarker Type

• Protein Biomarkers
• Genetic Biomarkers

Cancer/Tumor Profiling Market Assessment-by Technology

• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• In-situ hybridization (ISH)
• Immunohistochemistry (IHC)
• Other Technologies

Note: Other technologies include immunoassays, microarrays, mass spectrometers, Sanger sequencing, pyrosequencing, and fragment analysis

Cancer/Tumor Profiling Market Assessment-by Application

• Clinical Applications
• Research Applications

Cancer/Tumor Profiling Market Assessment-by Cancer Type

• Breast Cancer
• Colorectal Cancer
• Lung Cancer
• Prostate Cancer
• Lymphoma
• Leukemia
• Cervical Cancer
• Other Cancer Types

Note: Other cancer types include bladder cancer, melanoma, kidney cancer, stomach cancer, ovarian cancer, thyroid cancer, and head & neck cancers

Cancer/Tumor Profiling Market Assessment-by End User

• Pharmaceutical & Biopharmaceutical Companies
• Hospitals & Diagnostic Laboratories
• Academic & Research Institutes
• Contract Research Organizations (CROs)

Cancer/Tumor Profiling Market Assessment-by Geography

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • Italy
  • U.K.
  • Spain
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • Rest of Asia-Pacific
• Latin America
• Middle East & Africa

TABLE OF CONTENTS

1. Introduction

• 1.1. Market Definition and Scope
• 1.2. Market Ecosystem
• 1.3. Currency and Limitation
• 1.4. Key Stakeholders

2. Research Methodology

• 2.1. Research Approach
• 2.2. Process of Data Collection and Validation
  • 2.2.1. Secondary Research
  • 2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
• 2.3. Market Sizing and Forecast
  • 2.3.1. Market Size Estimation Approach
  • 2.3.2. Growth Forecast Approach
  • 2.3.3. Market Share Analysis
• 2.4. Assumptions for the Study

3. Executive Summary

4. Market Insights

• 4.1. Overview
• 4.2. Factors Affecting Market Growth
  • 4.2.1. Impact Analysis of Market Dynamics
  • 4.2.2. Factor Analysis
• 4.3. Regulatory Analysis
  • 4.3.1. North America
    • 4.3.1.1. U.S.
    • 4.3.1.2. Japan
    • 4.3.1.3. India
    • 4.3.1.4. Canada
  • 4.3.2. Europe
  • 4.3.3. Asia-Pacific
    • 4.3.3.1. China
    • 4.3.3.2. Japan
    • 4.3.3.3. India
  • 4.3.4. Latin America
  • 4.3.5. Middle East
• 4.4. Porter's Five Forces Analysis
  • 4.4.1. Bargaining Power of Buyers
  • 4.4.2. Bargaining Power of Suppliers
  • 4.4.3. Threat of Substitutes
  • 4.4.4. Threat of New Entrants
  • 4.4.5. Degree of Competition

5. Cancer/Tumor Profiling Market Assessment-by Biomarker Type

• 5.1. Overview
• 5.2. Genetic Biomarkers
• 5.3. Protein Biomarkers

6. Cancer/Tumor Profiling Market Assessment-by Cancer Type

• 6.1. Overview
• 6.2. Breast Cancer
• 6.3. Colorectal Cancer
• 6.4. Lung Cancer
• 6.5. Prostate Cancer
• 6.6. Lymphoma
• 6.7. Leukemia
• 6.8. Cervical Cancer
• 6.9. Other Cancer Types

7. Cancer/Tumor Profiling Market Assessment-by Technology

• 7.1. Overview
• 7.2. Next-Generation Sequencing (NGS)
• 7.3. Polymerase Chain Reaction (PCR)
• 7.4. In Situ Hybridization (ISH)
• 7.5. Immunohistochemistry (IHC)
• 7.6. Other Technologies

8. Cancer/Tumor Profiling Market Assessment-by Application

• 8.1. Overview
• 8.2. Research Applications
• 8.3. Clinical Applications

9. Cancer/Tumor Profiling Market Assessment-by End User

• 9.1. Overview
• 9.2. Pharmaceutical & Biopharmaceutical Companies
• 9.3. Hospitals & Diagnostic Laboratories
• 9.4. Academic & Research Institutes
• 9.5. Contract Research Organizations (CROs)

10. Cancer/Tumor Profiling Market Assessment-by Geography

• 10.1. Overview
• 10.2. North America
  • 10.2.1. U.S.
  • 10.2.2. Canada
• 10.3. Europe
  • 10.3.1. Germany
  • 10.3.2. France
  • 10.3.3. U.K.
  • 10.3.4. Italy
  • 10.3.5. Spain
  • 10.3.6. Rest of Europe
• 10.4. Asia-Pacific
  • 10.4.1. China
  • 10.4.2. Japan
  • 10.4.3. India
  • 10.4.4. Rest of Asia-Pacific
• 10.5. Latin America
• 10.6. Middle East & Africa

11. Competition Analysis

• 11.1. Overview
• 11.2. Key Growth Strategies
• 11.3. Competitive Benchmarking
• 11.4. Market Share Analysis (2022)
  • 11.4.1. Thermo Fisher Scientific Inc. (U.S.)
  • 11.4.2. Illumina, Inc. (U.S.)
  • 11.4.3. F. Hoffmann-La Roche Ltd (Switzerland)
  • 11.4.4. Exact Sciences Corporation (U.S.)
  • 11.4.5. Qiagen N.V. (Netherlands)
• 11.5. Competitive Dashboard
  • 11.5.1. Industry Leaders
  • 11.5.2. Market Differentiators
  • 11.5.3. Vanguards
  • 11.5.4. Emerging Companies

12. Company Profiles

• 12.1. Thermo Fisher Scientific, Inc.
• 12.2. Illumina, Inc.
• 12.3. Qiagen N.V.
• 12.4. F. Hoffmann-La Roche Ltd
• 12.5. Exact Sciences Corporation
• 12.6. Agilent Technologies, Inc.
• 12.7. NanoString Technologies, Inc.
• 12.8. HTG Molecular Diagnostics, Inc.
• 12.9. Agendia Inc.
• 12.10. Personalis, Inc.
• 12.11. Tempus Labs, Inc.

13. Appendix

• 13.1. Available Customization
• 13.2. Related Reports